Format

Send to

Choose Destination
See comment in PubMed Commons below
Swiss Med Wkly. 2013 Jun 6;143:w13801. doi: 10.4414/smw.2013.13801.

Potentials and pitfalls of clinical peptidomics and metabolomics.

Author information

1
Center of Laboratory Medicine University Institute of Clinical Chemistry Inselspital - Bern University Hospital Inselspital , Switzerland. alexander.leichtle@insel.ch

Abstract

Clinical peptidomics and metabolomics are two emerging "-omics" technologies with the potential not only to detect disease-specific markers, but also to give insight into the disease dependency of degradation processes and metabolic pathway alterations. However, despite their rapid evolution and major investments, a clinical breakthrough, such as the approval of a major cancer biomarker, is still out of sight. What are the reasons for this failure? In this review we focus on three important factors: sensitivity, specificity and the avoidance of bias. The way to clinical implementation of peptidomics and metabolomics is still hampered by many of the problems that had to be solved for genomics and proteomics in the past, as well as new ones that require the creation of new analytic, computational and interpretative techniques. The greatest challenge, however, will be the integration of information from different "-omics" subdisciplines into straightforward answers to clinical questions, for example, in the form of new, superior "meta-markers".

PMID:
23771768
DOI:
10.4414/smw.2013.13801
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for EMH Swiss Medical Publishers Ltd.
    Loading ...
    Support Center